全文获取类型
收费全文 | 124095篇 |
免费 | 47638篇 |
国内免费 | 2204篇 |
专业分类
耳鼻咽喉 | 2188篇 |
儿科学 | 5019篇 |
妇产科学 | 1455篇 |
基础医学 | 21819篇 |
口腔科学 | 5750篇 |
临床医学 | 17700篇 |
内科学 | 32253篇 |
皮肤病学 | 8468篇 |
神经病学 | 16148篇 |
特种医学 | 4493篇 |
外国民族医学 | 8篇 |
外科学 | 19467篇 |
综合类 | 4783篇 |
现状与发展 | 7篇 |
一般理论 | 38篇 |
预防医学 | 6996篇 |
眼科学 | 2604篇 |
药学 | 10525篇 |
33篇 | |
中国医学 | 2890篇 |
肿瘤学 | 11293篇 |
出版年
2024年 | 120篇 |
2023年 | 651篇 |
2022年 | 1726篇 |
2021年 | 3537篇 |
2020年 | 6424篇 |
2019年 | 12195篇 |
2018年 | 11629篇 |
2017年 | 12649篇 |
2016年 | 13383篇 |
2015年 | 13882篇 |
2014年 | 14202篇 |
2013年 | 14813篇 |
2012年 | 8130篇 |
2011年 | 8372篇 |
2010年 | 11333篇 |
2009年 | 7460篇 |
2008年 | 5017篇 |
2007年 | 3660篇 |
2006年 | 3448篇 |
2005年 | 3053篇 |
2004年 | 2550篇 |
2003年 | 2528篇 |
2002年 | 2341篇 |
2001年 | 1973篇 |
2000年 | 1751篇 |
1999年 | 1289篇 |
1998年 | 493篇 |
1997年 | 498篇 |
1996年 | 387篇 |
1995年 | 336篇 |
1994年 | 326篇 |
1993年 | 200篇 |
1992年 | 420篇 |
1991年 | 313篇 |
1990年 | 331篇 |
1989年 | 322篇 |
1988年 | 306篇 |
1987年 | 238篇 |
1986年 | 205篇 |
1985年 | 190篇 |
1984年 | 152篇 |
1983年 | 115篇 |
1982年 | 83篇 |
1981年 | 79篇 |
1980年 | 74篇 |
1979年 | 128篇 |
1978年 | 84篇 |
1977年 | 68篇 |
1975年 | 62篇 |
1974年 | 54篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
4.
5.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
6.
中医药防治动脉粥样硬化的研究具有良好的实践基础和应用前景,治疗方法可归于四类,即活血化瘀、化痰调脂、痰瘀同治、扶正祛邪,研究者辨证施治,多在临床上取得了满意的疗效。目前研究仍存在一些亟待解决的问题:首先,中医药防治动脉粥样硬化临床研究重复性差,缺乏大样本、多中心、高质量的临床研究及系统深入的实验研究;其次,对专家经验方及中药复方研究不够深入,临床药效物质基础不明确,缺乏对其作用机制的深入挖掘;再次,目前的研究不够系统和全面,主要集中在对动脉粥样硬化的形成和发展过程的研究,对斑块易损性研究相对较少。针对上述问题,今后应加强中医药治疗动脉粥样硬化的基础及临床研究,为治疗提供更加明确的理论依据和临床证据;同时,建立具有中医特色的研究模式,以中医宏观辨证理论为指导,利用现代医学技术,参考现代中药药理实验结果选药组方,扩大辨证选药思路,加强对中药方剂配伍规律的研究,以及对其有效成分的分离提取、鉴定和作用机制研究,并将传统组方理论与针对发病机制的对病治疗相结合,多角度、多层次探索中医药的作用机理。此外,应不断深入探索动脉粥样硬化的发病机制,并结合细胞工程、分子生物学及基因科学,积极研究中医药的药效学基础和机制。 相似文献
7.
8.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
9.
10.